Vinorelbine

Vinorelbine is a chemotherapy drug given by IV infusion or as an oral capsule, used to treat non-small cell lung cancer and pleural mesothelioma. It belongs to a class called vinca alkaloids and works by disrupting the internal scaffolding (microtubules) that cancer cells need to divide, slowing or stopping tumor growth.

Origin

Vinorelbine was developed in the 1980s by French researcher Pierre Potier and colleagues as a semisynthetic derivative of vinblastine, an alkaloid originally isolated from the Madagascar periwinkle (Catharanthus roseus, formerly Vinca rosea). It was approved in France in 1989 and by the U.S. FDA in 1994 under the brand name Navelbine.

Significance in Asbestos Context

Vinorelbine is one of the chemotherapy options used for patients with asbestos-related lung cancer and for pleural mesothelioma, particularly when first-line treatments such as cisplatin plus pemetrexed are not tolerated, stop working, or are not appropriate. For mesothelioma, it is sometimes used as a second-line or maintenance therapy and is among the agents studied in clinical trials specific to this disease. Treatment records showing vinorelbine use (along with imaging, pathology reports, and oncology notes) are important parts of the medical documentation that supports both clinical care and an asbestos claim, because they reflect the severity of disease and the costs and burdens of treatment.

Example Sentence

When the first round of chemotherapy stopped controlling her mesothelioma, her oncologist switched her to vinorelbine as a second-line treatment.

Related Terms

Chemotherapy, Pemetrexed, Cisplatin, Pleural Mesothelioma, Non-Small Cell Lung Cancer, Second-Line Therapy

Notes

• Ask your oncologist whether vinorelbine is being used as first-line, second-line, or maintenance therapy, and what the goal of treatment is (shrinking tumor, controlling growth, symptom relief).
• Watch for and promptly report side effects: low white blood cell counts (infection risk), numbness or tingling in hands and feet (neuropathy), constipation, fatigue, and injection-site irritation; oral vinorelbine can also cause nausea.
• Keep copies of all infusion records, oncology notes, prescription records, and lab results. These document the course of treatment and the costs and burdens of your disease for both medical and legal purposes.
• If you are considering or enrolled in a clinical trial, ask whether vinorelbine is part of the regimen and how it compares to standard options for your specific diagnosis.